Our study on patient-reported outcomes in multiple myeloma published in The Lancet Haematology!
We are excited to announce that Damian Mikulski, MD, PhD, has co-authored a landmark study titled “Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7).” This groundbreaking research has been published in the prestigious journal, The Lancet Haematology (IF: 17.7). Multiple myeloma […]